CompletedPhase 3NCT00278408
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
- Principal Investigator
- Michael G.M. Pfreundschuh, MD †Universitaetsklinikum des Saarlandes
- Intervention
- filgrastim(biological)
- Enrollment
- 700 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2006 – 2018
Study locations (30)
- Rigshospitalet, Department of Hematology, Copenhagen, Denmark
- Amtssygehuset i Herlev, Herlev, Denmark
- GMP Tummes/Weinberg, Aachen, Germany
- Klinikum St. Marien, Amberg, Germany
- Klinikum Augsburg, Augsburg, Germany
- Kreiskrankenhaus Aurich, Aurich, Germany
- Klinikum Bayreuth, Bayreuth, Germany
- Charite - Campus Charite Mitte, Berlin, Germany
- Charite University Hospital - Campus Virchow Klinikum, Berlin, Germany
- Helios Klinikum Berlin-Buch, Department of Hematology and Stem Cell Transplantation, Berlin, Germany
- Franziskus Hospital, Bielefeld, Germany
- Augusta-Kranken-Anstalt gGmbH, Bochum, Germany
- Johanniter Krankenhaus Bonn, Bonn, Germany
- Universitätsklinikum Bonn, Bonn, Germany
- Staedtisches Klinikum Braunschweig, Braunschweig, Germany
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00278408 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha